[October 23, 2014]

Igenica Biotherapeutics to Present New Data on Proprietary SNAP Antibody Drug Conjugate Technology at Upcoming World ADC Summit

Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the company will present new data on ADCs utilizing its SNAP site-specific ADC linker technology at a plenary session of the 2015 World ADC (News - Alert) Summit, being held October 26-29, 2014 in San Diego.

Drug companies are aggressively pursuing ADCs, a powerful new class of anti-cancer medicines comprised of a monoclonal antibody, a linker and a payload. The current generation of ADCs offers limited benefits to patients because they are heterogeneous drug mixtures containing variants with sub-optimal pharmaceutical properties. Igenica's SNAP technology is based on a proprietary linker that overcomes the major limitations of current approaches by enabling a fast and robust chemically-driven method for linking any cancer targeting antibody and small molecule cytotoxic drug to produce ADC products with optimal and uniform ratios of drug to antibody. Igenica has successfully applied its SNAP technology to synthesize ADCs using multiple antibodies and a variety of payloads.

At the World ADC Summit, Igenica will present new data that compare the biophysical properties, in vitro potency, in vivo efficacy and pharmacokinetics of ADCs containing Igeica's SNAP linkers compared to conventional ADCs. These findings validate the superiority of SNAP linkers in terms of ADC uniformity, pharmacokinetics, stability and in vivo efficacy as compared to conventional ADCs. SNAP linkers also enable improved process efficiency, including a fast, robust chemical conjugation and the ability to use traditional antibody production systems, in contrast to ADC approaches that require protein engineering.

In addition, Igenica will be recognized for its innovative SNAP technology as a finalist in the Best Scientific Innovation Category during the World ADC Awards ceremony, being held in conjunction with the World ADC Summit, on Sunday, October 26, 2014.

"Igenica's SNAP technology represents a breakthrough in ADC uniformity, process efficiency and drug product profile for the next-generation of homogeneous ADCs," said Mary Haak-Frendscho, Ph.D., chief executive officer of Igenica. "Our innovative platform has the potential to produce drugs with lower toxicity and higher efficacy, representing an important benefit to cancer patients. We are proud that our cutting-edge technology will be featured as a finalist in the Best Scientific Innovation category at the World ADC Awards Ceremony."

Igenica's presentation details are as follows:

Date and Time: Tuesday, October 28, 2014, 2:30 p.m.

Presentation Title: SNAP: A Chemistry Driven Approach to Uniform ADCs

Presenter: Randall Halcomb, Ph.D., Vice President, Chemistry, Igenica Biotherapeutics

About Igenica Biotherapeutics

Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. SNAP technology is named for its superior pharmacological drug profile, use of native antibodies, adaptable format and process efficiency. Igenica is the only small biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica's integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. For more information, please visit www.igenica.com.

[ Back To TMCnet.com's Homepage ]